<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00311909</url>
  </required_header>
  <id_info>
    <org_study_id>UHC DBS TS</org_study_id>
    <nct_id>NCT00311909</nct_id>
  </id_info>
  <brief_title>Thalamic Deep Brain Stimulation for Tourette Syndrome</brief_title>
  <official_title>Thalamic Deep Brain Stimulation for Tourette Syndrome: A Prospective Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether deep brain stimulation is effective at&#xD;
      reducing tic frequency and severity in adults with Tourette syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>modified Rush Video Rating Scale (mRVRS)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>at defined points including baseline and 3 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>tic counts (on video recording)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Yale Global Tourette Severity Scale (YGTSS)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tourette Syndrome Symptom List (TSSL)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Visual Analog Scale (VAS)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological battery</measure>
  </secondary_outcome>
  <enrollment>5</enrollment>
  <condition>Tourette Syndrome</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Thalamic deep brain stimulation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 18 or older&#xD;
&#xD;
          -  Diagnosis of Tourette Syndrome by DSM-IV&#xD;
&#xD;
          -  Tic frequency at least one per minute at screening&#xD;
&#xD;
          -  prior failure of at least two dopamine receptor or presynaptic blockers&#xD;
&#xD;
          -  negative impact on quality of life&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  significant structural brain lesion (on imaging studies)&#xD;
&#xD;
          -  significant dementia&#xD;
&#xD;
          -  severe head trauma preceding onset of tics&#xD;
&#xD;
          -  use of dopamine receptor blockers prior to recognition of tics&#xD;
&#xD;
          -  prior implanted electrical device&#xD;
&#xD;
          -  electroconvulsive therapy (ECT) within 24 months&#xD;
&#xD;
          -  suicide attempt within 12 months&#xD;
&#xD;
          -  significant sociopathic personality&#xD;
&#xD;
          -  current or planned pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J Maciunas, MD MPH FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2006</verification_date>
  <study_first_submitted>April 5, 2006</study_first_submitted>
  <study_first_submitted_qc>April 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2006</study_first_posted>
  <last_update_submitted>April 5, 2006</last_update_submitted>
  <last_update_submitted_qc>April 5, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2006</last_update_posted>
  <keyword>Tourette Syndrome</keyword>
  <keyword>Deep Brain Stimulation</keyword>
  <keyword>Video assessment</keyword>
  <keyword>YGTSS</keyword>
  <keyword>TSSL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tourette Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

